Apixaban Versus Aspirin to Reduce Cognitive Decline After Cryptogenic Stroke and Atrial Cardiopathy: ARCADIA-Cognition Study.

ABSTRACT:

Background

ARCADIA (Atrial Cardiopathy and Antithrombotic Drugs in Prevention After Cryptogenic Stroke), a secondary stroke prevention study comparing apixaban versus aspirin for cryptogenic stroke and biomarkers of atrial cardiopathy, ended prematurely for futility. In the ARCADIA-Cognition study we hypothesized that cognitive decline would be slower in the apixaban arm due to less microembolization.

Methods

ARCADIA subjects on study drug and eligible for magnetic resonance imaging participated in ARCADIA-CSI (ARCADIA-Cognition and Silent Infarction). Cognitive tests were administered centrally by telephone ≥3 months after the ARCADIA index stroke and yearly thereafter. Composite Z scores were the means of 5 standardized cognitive tests. Trajectories of the composite

SUBMITTER: Lazar RM 

PROVIDER: S-EPMC12554400 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature